Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, has renewed its long-standing enterprise partnership with ClinChoice, a global contract research organization (CRO). Under this new agreement, ClinChoice will utilize the Medidata Platform to streamline study data and supply management, boost trial efficiency, and accelerate growth as a full-service CRO in Asia, Europe, and North America. ClinChoice also plans to prioritize Clinical Data Studio accreditation, further enhancing its capabilities through a transformative AI-powered data quality management experience.
ClinChoice’s commitment in utilizing Medidata’s solution has spanned over a decade, facilitating secure connections among patients, sites, and sponsors within a unified cloud environment. As an early adopter, ClinChoice played a critical role during the pandemic by deploying Rave RTSM’s Direct-to-Patient model, which maintained patient access and optimized inventory across diverse regions and regulatory requirements. By integrating Medidata’s solutions, ClinChoice continues to strengthen its operational efficiency and position itself for growth in today’s increasingly complex clinical trial landscape.
“Since our first implementation of Medidata Rave EDC in 2011, our partnership with Medidata has supported our development, starting in the U.S., then China, and eventually to the wider global stage,” said Ling Zhen, Global Chairman and CEO of ClinChoice. "We are delighted to extend our work together to include Medidata’s Clinical Data Studio and other advanced technologies to further boost our expansion."
“ClinChoice’s dedication to innovation and patient-centered approaches makes them an invaluable partner,” said Edwin Ng, senior vice president and general manager, APAC, Medidata. “With this renewed partnership, we look forward to empowering ClinChoice with Medidata’s advanced solutions to further streamline their trial operations, expand their global reach, and accelerate access to life-changing therapies for patients worldwide.”
To view the original press release, please click here.
